GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Sale Of Property, Plant, Equipment

Cleo Diagnostics (ASX:COV) Sale Of Property, Plant, Equipment : A$ Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Sale Of Property, Plant, Equipment?

Cleo Diagnostics's sale of property, plant, equipment for the six months ended in Dec. 2023 was A$0.00 Mil. It means Cleo Diagnostics gained A$0.00 Mil from selling property, plant, and equipment.

Compared with last quarter (A$0.00 Mil in Jun. 2023 ), Cleo Diagnostics gained the same money from selling property, plant, and equipment in Dec. 2023 (A$0.00 Mil).


Cleo Diagnostics Sale Of Property, Plant, Equipment Historical Data

The historical data trend for Cleo Diagnostics's Sale Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Sale Of Property, Plant, Equipment Chart

Cleo Diagnostics Annual Data
Trend Jun23
Sale Of Property, Plant, Equipment
-

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23
Sale Of Property, Plant, Equipment - - -

Cleo Diagnostics Sale Of Property, Plant, Equipment Calculation

The amount earned to sell PPE.


Cleo Diagnostics Sale Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Sale Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleo Diagnostics (ASX:COV) Business Description

Traded in Other Exchanges
N/A
Address
480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines